Molecular events leading to HPV-induced high grade neoplasia

Papillomavirus Research

Volumn 2, Issue , 2016, Pages 85-88

  Wilting, Saskia M ^a   Steenbergen, Renske D M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER; ONCOPROTEIN;

ADENOCARCINOMA IN SITU; CANCER GRADING; CARCINOGENESIS; CELL DIVISION; CELL TRANSFORMATION; CERVICAL CARCINOGENESIS; CHROMOSOME MUTATION; DISEASE COURSE; DNA DAMAGE; DNA METHYLATION; E6 VIRAL ONCOGENE; E7 VIRAL ONCOGENE; EARLY DIAGNOSIS; GENE EXPRESSION; GENE SILENCING; HUMAN; M PHASE CELL CYCLE CHECKPOINT; MOLECULAR PATHOLOGY; MUTATION ACCUMULATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRECANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS ONCOGENE; WART VIRUS; COMPLICATION; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; METABOLISM; NEOPLASM; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOLOGY; VIROLOGY;

CARCINOGENESIS; HOST-PATHOGEN INTERACTIONS; HUMANS; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84964374724     PISSN: None     EISSN: 24058521     Source Type: Journal    
DOI: 10.1016/j.pvr.2016.04.003     Document Type: Review

References (39)

1. Pisani P., Bray F., Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer 2002, 97:72-81.
2. Kulis M., Esteller M. DNA methylation and cancer. Adv. Genet. 2010, 70:27-56.
3. Au Yeung C.L., Tsang W.P., Tsang T.Y., Co N.N., Yau P.L., Kwok T.T. HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53. Oncol. Rep. 2010, 24:1599-1604.
4. Burgers W.A., Blanchon L., Pradhan S., de L.Y., Kouzarides T., Fuks F. Viral oncoproteins target the DNA methyltransferases. Oncogene 2007, 26:1650-1655.
5. Leonard S.M., Wei W., Collins S.I., Pereira M., Diyaf A., Constandinou-Williams C., et al. Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women. Carcinogenesis 2012, 33:1286-1293.
6. Li L., Xu C., Long J., Shen D., Zhou W., Zhou Q., et al. E6 and E7 gene silencing results in decreased methylation of tumor suppressor genes and induces phenotype transformation of human cervical carcinoma cell lines. Oncotarget 2015, 6:23930-23943.
7. Sartor M.A., Dolinoy D.C., Jones T.R., Colacino J.A., Prince M.E., Carey T.E., et al. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 2011, 6:777-787.
8. Steenbergen R.D., Snijders P.J., Heideman D.A., Meijer C.J. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat. Rev. Cancer 2014, 14:395-405.
9. Wentzensen N., Sherman M.E., Schiffman M., Wang S.S. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol. Oncol. 2009, 112:293-299.
10. Jimenez-Wences H., Peralta-Zaragoza O., Fernandez-Tilapa G. Human papilloma virus, DNA methylation and microRNA expression in cervical cancer. Oncol. Rep. 2014, 31:2467-2476.
11. Bierkens M., Hesselink A.T., Meijer C.J., Heideman D.A., Wisman G.B., van der Zee A.G., et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int. J. Cancer 2013, 133:1293-1299.
12. De Strooper L.M., Meijer C.J., Berkhof J., Hesselink A.T., Snijders P.J., Steenbergen R.D., et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev. Res. 2014, 7:1251-1257.
13. Huisman C., Wisman G.B., Kazemier H.G., van Vugt M.A., van der Zee A.G., Schuuring E., et al. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by artificial transcription factors. Mol. Oncol. 2013, 7:669-679.
14. Bierkens M., Krijgsman O., Wilting S.M., Bosch L., Jaspers A., Meijer G.A., et al. Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer 2013, 52:56-68.
15. Chung M.T., Lai H.C., Sytwu H.K., Yan M.D., Shih Y.L., Chang C.C., et al. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol. Oncol. 2009, 112:646-653.
16. Lando M., Fjeldbo C.S., Wilting S.M., Snoek C., Aarnes E.K., Forsberg M.F., et al. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer. Epigenetics 2015, 10:970-980.
17. Overmeer R.M., Henken F.E., Bierkens M., Wilting S.M., Timmerman I., Meijer C.J., et al. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J. Pathol. 2009, 219:327-336.
18. Snellenberg S., Cillessen S.A., Van C.W., Bosch L., Meijer C.J., Snijders P.J., et al. Methylation-mediated repression of PRDM14 contributes to apoptosis evasion in HPV-positive cancers. Carcinogenesis 2014, 35:2611-2618.
19. Steenbergen R.D., Kramer D., Braakhuis B.J., Stern P.L., Verheijen R.H., Meijer C.J., et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J. Natl. Cancer Inst. 2004, 96:294-305.
20. Wang F., Li Y., Zhou J., Xu J., Peng C., Ye F., et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am. J. Pathol. 2011, 179:2580-2588.
21. Wilting S.M., van Boerdonk R.A., Henken F.E., Meijer C.J., Diosdado B., Meijer G.A., et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol. Cancer 2010, 9:167.
22. Wilting S.M., Verlaat W., Jaspers A., Makazaji N.A., Agami R., Meijer C.J., et al. Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics 2013, 8:220-228.
23. Henken F.E., Wilting S.M., Overmeer R.M., van Rietschoten J.G., Nygren A.O., Errami A., et al. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br. J. Cancer 2007, 97:1457-1464.
24. Schütze D.M., Kooter J.M., Wilting S.M., Meijer C.J., Quint W., Snijders P.J., et al. Longitudinal assessment of DNA methylation changes during HPVE6E7-induced immortalization of primary keratinocytes. Epigenetics 2015, 10:73-81.
25. Duensing S., Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int. J. Cancer 2004, 109:157-162.
26. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 2010, 10:550-560.
27. Bodelon C., Vinokurova S., Sampson J.N., den Boon J.A., Walker J.L., Horswill M.A., et al. Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis 2015.
28. Ojesina A.I., Lichtenstein L., Freeman S.S., Pedamallu C.S., Imaz-Rosshandler I., Pugh T.J., et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014, 506:371-375.
29. Hu Z., Zhu D., Wang W., Li W., Jia W., Zeng X., et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat. Genet. 2015, 47:158-163.
30. Vinokurova S., Wentzensen N., Kraus I., Klaes R., Driesch C., Melsheimer P., et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008, 68:307-313.
31. Thomas L.K., Bermejo J.L., Vinokurova S., Jensen K., Bierkens M., Steenbergen R., et al. Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract - a systematic review and meta-analysis. Eur. J. Cancer 2014, 50:85-98.
32. Lou H., Villagran G., Boland J.F., Im K.M., Polo S., Zhou W., et al. Genome analysis of latin american cervical cancer: frequent activation of the PIK3CA pathway. Clin. Cancer Res. 2015, 21:5360-5370.
33. Wilting S.M., Steenbergen R.D., Tijssen M., van Wieringen W.N., Helmerhorst T.J., van Kemenade F.J., et al. Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas. Cancer Res. 2009, 69:647-655.
34. Bierkens M., Wilting S.M., van Wieringen W.N., van Kemenade F.J., Bleeker M.C., Jordanova E.S., et al. Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. Int. J. Cancer 2012, 131:E579-E585.
35. Schütze D.M., Krijgsman O., Snijders P.J., Ylstra B., Weischenfeldt J., Mardin B.R., et al. Immortalization capacity of HPV types is inversely related to chromosomal instability. Oncotarget 2016, 10.18632/oncotarget.8058. [Epub ahead of print].
36. Spaans V.M., Trietsch M.D., Peters A.A., Osse M., Ter H.N., Fleuren G.J., et al. Precise classification of cervical carcinomas combined with somatic mutation profiling contributes to predicting disease outcome. PLoS One 2015, 10:e0133670.
37. Vartanian J.P., Guetard D., Henry M., Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 2008, 320:230-233.
38. Verlaat W., Snijders P., van Moorsel M., Bleeker M., Rozendaal L., Sie D., et al. Somatic mutation in PIK3CA is a late event in cervical carcinogenesis. J. Pathol. 2015, 1:207-211.
39. Vink M.A., Bogaards J.A., van Kemenade F.J., de Melker H.E., Meijer C.J., Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am. J. Epidemiol. 2013, 178:1161-1169.